Meeting
2016 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
Authors
Antonio Marcilio Padula Omuro
Memorial Sloan Kettering Cancer Center, New York, NY
Antonio Marcilio Padula Omuro , Kathryn Beal , Katharine Anne McNeill , Alissa A. Thomas , Xuling Lin , Thomas Joseph Kaley , Lisa Marie DeAngelis , Ingo K. Mellinghoff , Eli L. Diamond , Timothy An-thy Chan , Robert J. Young , Yoshiya Yamada , Greg Gorman , Michael Lamson , Linda M. Bavisotto , Rashida A. Karmali
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01107522
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2060)
DOI
10.1200/JCO.2016.34.15_suppl.2060
Abstract #
2060
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang
Poster
2015 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
First Author: Alissa A. Thomas
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran
Poster
2022 ASCO Annual Meeting
Phase IB trial of pegylated arginine deiminase (ADI-PEG 20) plus radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
First Author: John S. Bomalaski